15Apr 2020

REMDESIVIR AND COVID-19

  • Department of Surgery, Faculty of Medicine, University of Colombo, Sri Lanka.
  • Department of Zoology and Environment Sciences, Faculty of Science, University of Colombo, Sri Lanka.
  • Nawaloka Hospital Research and Education Foundation, Nawaloka Hospitals, Colombo, Sri Lanka.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

The SARS-CoV-2 virus was first encountered in Wuhan, China in December 2019. At the present time, coronavirus disease 2019 (Covid-19) affects more than 170 countries. Several groups are carrying out intense research on drugs and vaccines to treat or prevent Covid-19. We have outlined aspects relating to Remdesivir, in treating RNA viral infections and its potential role in controlling SARS-Cov-2 infections.

  1. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan. T.P., Lu, X. et al. (2018) Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio.,9
  2. Brown, A.J., Won, J.J., Graham, R.L., Dinnon, K.H., Sims, A.C., Feng, J.Y. et al. (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral research.,169: 104541
  3. de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T. et al. (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences., 117: 6771 -76
  4. Gordon, C.J., Tchesnokov, E.P., Feng, J.Y., Porter, D.P., Gotte, M,.(2020) The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem,. April 10 (Epub ahead of print)
  5. Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A. et al. (2020) Compassionate use of Reemdesivir for patients with severe Covid-19. N Engl J Med., April 10 (Epub ahead of print)
  6. Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H. et al. (2020) First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 382 (10): 929?936
  7. Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L. et al. (2017) GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific reports.,7: 43395
  8. S., Dodd, L.E., Davey, R.T., TshianiMbaya, O., Proschan, M., Mukadi, D. et al. (2019) A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England journal of medicine., 381: 2293-2303
  9. Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B. et al. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine.,9:396
  10. Sheahan, T.P., Sims, A.C., Leist, S.R, Schafer, A., Won, J., Brown, A.J. et al. (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications,. 11: 222
  11. Siegel, D., Hui, H.C., Doerffler, E., Clarke, M.O., Chun, K., Zhang, L. et al. (2017) Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of medicinal chemistry,.60: 1648-1661
  12. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M. et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res,. 30 (3): 269?271.
  13. Warren, T.K., Jordan, R., Lo, M.K, Ray, A.S, Mackman, R.L., Soloveva, V. et al.(2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature,. 531: 381-385
  14. Wu, Z., McGoogan,J.M..(2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA,.323: 1239-1242.

[Suranjith L Seneviratne, Roshan Niloofa, Ishan De Zoysa, Sanjay de Mel and Visula Abeysuriya (2020); REMDESIVIR AND COVID-19 Int. J. of Adv. Res. 8 (Apr). 565-567] (ISSN 2320-5407). www.journalijar.com

Prof Suranjith L Seneviratne
Department of Surgery, Faculty of Medicine, University of Colombo, Sri Lanka.

DOI:

Article DOI: 10.21474/IJAR01/10811      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10811

Download Full Paper

Download PDF No. of Downloads: 34 | No. of Views: 123